» Articles » PMID: 16877463

Validity of the Saint George's Respiratory Questionnaire in the Evaluation of the Health-related Quality of Life in Patients with Interstitial Lung Disease Secondary to Systemic Sclerosis

Overview
Specialty Rheumatology
Date 2006 Aug 1
PMID 16877463
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Interstitial lung disease (ILD) profoundly affects the health-related quality of life (HRQoL) in patients with systemic sclerosis (SSc). We tested the validity of the Saint George's Respiratory Questionnaire (SGRQ), a lung-specific HRQoL-evaluation tool, in a population of SSc patients with ILD.

Methods: Twenty-eight consecutive SSc patients with a restrictive pulmonary involvement, defined as a forced vital capacity <80% of the predicted, with no pulmonary hypertension were considered. All the patients filled in the Medical Research Council (MRC) scale for perceived breathlessness, the SGRQ and the Disability Index of the Health Assessment Questionnaire (HAQ DI), and underwent evaluation with complete pulmonary function testing (PFT), 6-minute walk distance (6MWD) and high-resolution computed tomography (HRCT).

Results: The SGRQ 'activity' scores inversely correlated with the 6MWD (r = -0.86, P < 0.001) and forced vital capacity percentage of predicted values (r = -0.47) and directly correlated with HRCT (r = 0.41, P < 0.05), MRC (rho = 0.64, P < 0.001) or HAQ DI scores (r = 0.62, P < 0.001), independently of disease duration or subset. On the contrary, HAQ DI scores were influenced by those variables and corrected correlations with 6MWD (r = 0.56, P < 0.001) or HRCT scores (r = 0.36, P = NS) were less strong than those observed with the SGRQ.

Conclusions: The SGRQ, although not specifically designed for scleroderma, is a valid respiratory-specific questionnaire for the evaluation of HRQoL in patients with SSc-related ILD. The SGRQ performs better in relation to exercise capacity and lung imaging than other non-respiratory-specific questionnaires widely used in scleroderma studies. Further studies are needed to address its ability to assess changes over time or in response to therapy.

Citing Articles

Quality of life in scleroderma-related interstitial lung disease and its association with respiratory clinical parameters.

Ponniah T, Wong C, Ng C, Raja J J Scleroderma Relat Disord. 2025; :23971983251318827.

PMID: 40013234 PMC: 11851579. DOI: 10.1177/23971983251318827.


Reference values for the 1-minute sit-to-stand test to assess functional capacity and short-term mortality in people with idiopathic pulmonary fibrosis and fibrotic connective tissue related interstitial lung diseases: a prospective real-world....

Tsai M, Huang K, Hsu C, Yu Y, Fu P BMC Pulm Med. 2025; 25(1):61.

PMID: 39905346 PMC: 11796153. DOI: 10.1186/s12890-025-03521-3.


Systemic sclerosis associated interstitial lung disease: a survey of current practices in France.

Nicolas A, Leroy S, Mouthon L, Uzunhan Y, Cottin V, Mekinian A Ther Adv Musculoskelet Dis. 2023; 15:1759720X231159712.

PMID: 37187855 PMC: 10176589. DOI: 10.1177/1759720X231159712.


Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.

Kreuter M, Bonella F, Blank N, Riemekasten G, Muller-Ladner U, Henes J Rheumatology (Oxford). 2023; 62(9):3067-3074.

PMID: 36708008 PMC: 10473195. DOI: 10.1093/rheumatology/kead023.


Association of Symptoms of Gastroesophageal Reflux, Esophageal Dilation, and Progression of Systemic Sclerosis-Related Interstitial Lung Disease.

Volkmann E, Tashkin D, Leng M, Kim G, Goldin J, Roth M Arthritis Care Res (Hoboken). 2022; 75(8):1690-1697.

PMID: 36504432 PMC: 10258217. DOI: 10.1002/acr.25070.